Massive reanalysis of genome data solves case of the lethal genes

User rating: 4.9 / 5 after 13 vote(s)

It is better to be looked over than overlooked, Mae West supposedly said. These are words of wisdom for genome data-miners of today. Data that goes unnoticed, despite its widespread availability, can reveal extraordinary insights to the discerning eye. Such is the case of a systematic analysis by the U.S. Department of Energy Joint Genome Institute (DOE JGI) of the massive backlog of microbial genome sequences from the public databases.


Full story »

All News summaries from Medicine & Health news
All News summaries for October 18, 2007

5 things you didn't know about... buying medication online

4 hours ago | User rating: not rated yet
Cynthia Reilly, director of the practice development division of the American Society of Health-Systems Pharmacists, offers advice for shopping online:

Scientists go chatting to hear kids' drug concerns

4 hours ago | User rating: not rated yet
(AP) -- It's nothing to LOL about. Students these days often have ready access to marijuana, alcohol and tobacco but they don't feel comfortable talking about the ramifications. So, some of the nation's government ...

End-of-life discussions with physicians may have benefits for patients and caregivers

4 hours ago | User rating: not rated yet
Terminally ill patients who had end-of-life discussions with physicians were not more likely to experience emotional distress, received less aggressive medical care in their final week of life and had a better quality of ...

Older renal cancer patients appear to benefit from sorafenib treatment

4 hours ago | User rating: not rated yet
Older and younger patients with renal cancer derive similar benefit from sorafenib therapy and tolerate the drug equally well, according to a study published online October 7 in the Journal of the National Cancer Institute.

Use of medication for enlarged prostate not associated with increased risk of hip fracture

4 hours ago | User rating: not rated yet
Use of a class of medications for treating an enlarged prostate, known as 5-α reductase inhibitors, are not associated with an increased hip fracture risk, according to a study in the October 8 issue of JAMA.